- Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.Lu, Shun; Wu, Lin; Zhang, Wei; Zhang, Peng; Wang, Wenxiang; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Mei, Jiandong; Yang, Lin; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Shan, Jinlu; Yang, Nong; Chen, Yuping; Tian, HuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.被引 29
- Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutationsWang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)Cheng, Y.; Liu, Y.; Zhang, W.; Wu, L.; Zhou, C.; Wang, D.; Xia, B.; Bi, M.; Fu, X.; Li, C.; Chen, G.; Lv, D.; Zhao, Y.; Huang, J.; Li, M.; Yi, T.; Huang, X.; Yang, R.; Chen, Z.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study
6被引15阅读
